Cargando…

Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment

The water-soluble glycofullerenes GF1 and GF2 were synthesized using two-step modified Bingel-Hirsch methodology. Interestingly, we identified buckyballs as a novel class of non-receptor Src kinases inhibitors. The evaluated compounds were found to inhibit Fyn A and BTK proteins with IC(50) values i...

Descripción completa

Detalles Bibliográficos
Autores principales: Serda, Maciej, Malarz, Katarzyna, Mrozek-Wilczkiewicz, Anna, Wojtyniak, Marcin, Musioł, Robert, Curley, Steven A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959220/
https://www.ncbi.nlm.nih.gov/pubmed/31937861
http://dx.doi.org/10.1038/s41598-019-57155-7
_version_ 1783487548687908864
author Serda, Maciej
Malarz, Katarzyna
Mrozek-Wilczkiewicz, Anna
Wojtyniak, Marcin
Musioł, Robert
Curley, Steven A.
author_facet Serda, Maciej
Malarz, Katarzyna
Mrozek-Wilczkiewicz, Anna
Wojtyniak, Marcin
Musioł, Robert
Curley, Steven A.
author_sort Serda, Maciej
collection PubMed
description The water-soluble glycofullerenes GF1 and GF2 were synthesized using two-step modified Bingel-Hirsch methodology. Interestingly, we identified buckyballs as a novel class of non-receptor Src kinases inhibitors. The evaluated compounds were found to inhibit Fyn A and BTK proteins with IC(50) values in the low micromolar range, with the most active compound at 39 µM. Moreover, we have demonstrated that formation of protein corona on the surface of [60]fullerene derivatives is changing the landscape of their activity, tuning the selectivity of obtained carbon nanomaterials towards Fyn A and BTK kinases. The performed molecular biology studies revealed no cytotoxicity and no influence of engineered carbon nanomaterials on the cell cycle of PANC-1 and AsPC-1 cancer cell lines. Incubation with the tested compounds resulted in the cellular redox imbalance triggering the repair systems and influenced the changing of protein levels.
format Online
Article
Text
id pubmed-6959220
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69592202020-01-16 Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment Serda, Maciej Malarz, Katarzyna Mrozek-Wilczkiewicz, Anna Wojtyniak, Marcin Musioł, Robert Curley, Steven A. Sci Rep Article The water-soluble glycofullerenes GF1 and GF2 were synthesized using two-step modified Bingel-Hirsch methodology. Interestingly, we identified buckyballs as a novel class of non-receptor Src kinases inhibitors. The evaluated compounds were found to inhibit Fyn A and BTK proteins with IC(50) values in the low micromolar range, with the most active compound at 39 µM. Moreover, we have demonstrated that formation of protein corona on the surface of [60]fullerene derivatives is changing the landscape of their activity, tuning the selectivity of obtained carbon nanomaterials towards Fyn A and BTK kinases. The performed molecular biology studies revealed no cytotoxicity and no influence of engineered carbon nanomaterials on the cell cycle of PANC-1 and AsPC-1 cancer cell lines. Incubation with the tested compounds resulted in the cellular redox imbalance triggering the repair systems and influenced the changing of protein levels. Nature Publishing Group UK 2020-01-14 /pmc/articles/PMC6959220/ /pubmed/31937861 http://dx.doi.org/10.1038/s41598-019-57155-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Serda, Maciej
Malarz, Katarzyna
Mrozek-Wilczkiewicz, Anna
Wojtyniak, Marcin
Musioł, Robert
Curley, Steven A.
Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
title Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
title_full Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
title_fullStr Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
title_full_unstemmed Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
title_short Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
title_sort glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959220/
https://www.ncbi.nlm.nih.gov/pubmed/31937861
http://dx.doi.org/10.1038/s41598-019-57155-7
work_keys_str_mv AT serdamaciej glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment
AT malarzkatarzyna glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment
AT mrozekwilczkiewiczanna glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment
AT wojtyniakmarcin glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment
AT musiołrobert glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment
AT curleystevena glycofullerenesasnonreceptortyrosinekinaseinhibitorstowardsbetternanotherapeuticsforpancreaticcancertreatment